Journal of Clinical Oncology
Articles in this Issue
Intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumors: A multicenter phase Ib/IIa trial with expansion cohorts in melanoma and soft tissue sarcoma patients (SAKK 66/17).
2610 Background: This trial combines the novel adjuvant immunomodulator IP-001, a glycan polymer, with laser ablation in p...
Age and HIV status as survival predictors in HHV8-positive diffuse large B-cell lymphoma: The largest population-based analysis to date.
7084 Background: HHV8-positive Diffuse Large B Cell Lymphoma (HHV8+ DLBCL) is a rare and aggressive subtype of Non-Hodgkin...
EPCORE NHL-6: Phase 2 study of subcutaneous (SC) epcoritamab as outpatient treatment for 2L+ relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
e19003 Background: Epcoritamab, a CD3×CD20 bispecific antibody approved for R/R DLBCL, is administered SC with inpatient m...
Interrupting HEG1/Cx43 interaction to promote cuproptosis via inhibiting gap junction to overcome glioblastoma radioresistance.
2047 Background: Glioblastoma (GBM) is the most common and aggressive primary malignant tumor of the central nervous syste...
Ocular toxicity and safety profile of mirvetuximab soravtansine in ovarian cancer: A systematic review and meta-analysis of clinical trials and real-world studies.
5558 Background: Mirvetuximab soravtansine (MIRV) is a folate receptor alpha (FRα)–targeting antibody–drug conjugate appro...
Integrated expression analysis of microRNA and its associated gene network in thyroid cancer.
e18042 Background: Thyroid cancer, the most common endocrine malignancy, is increasing in incidence globally, underscoring...
Age-related disparities in catastrophic health expenditures among cancer survivors in the United States: Evidence from MEPS, 2018-2022.
e23108 Background: Cancer survivorship carries substantial financial burden, yet age-related differences in catastrophic h...
A randomized phase II study of pembrolizumab plus paclitaxel with or without bevacizumab in PD-L1–positive recurrent triple-negative breast cancer previously treated with perioperative immune checkpoint inhibitors: WJOG16522B (PRELUDE) trial.
TPS1163 Background: Perioperative pembrolizumab combined with chemotherapy has become a standard of care for patients with...
Primary cutaneous diffuse large B-cell lymphoma, leg type: A systematic review of morphological mimics and atypical anatomical presentations.
e19078 Background: Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type (PCDLBCL-LT) is characterized by an aggressiv...
Overcoming immunotherapy resistance in advanced melanoma through radiotherapy: A prospective observational study.
e21501 Background: Outcomes for patients with advanced melanoma have improved since the integration of immune checkpoint i...
Belzutifan plus lenvatinib versus cabozantinib in post–PD-(L)1 renal cell carcinoma (RCC): Health-related quality-of-life (HRQoL) outcomes in the phase 3 LITESPARK-011 study.
e23270 Background: Belzutifan + lenvatinib significantly improved PFS and ORR vs cabozantinib, and had manageable safety,...
Neighborhood-level disadvantage and disparities in treatment and recurrence in tenosynovial giant cell tumor.
e23528 Background: Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive neoplasm arising from the synovial l...
Actionable germline findings in endometrial cancer from a large multigene panel tested cohort.
10611 Background: Although most endometrial cancers (EC) are sporadic, 2–6% arise in the setting of Lynch syndrome (LS) or...
5–aminolevulinic acid fluorescence-guided surgery vs conventional white-light resection in glioma: A systematic review and meta-analysis.
e14076 Background: Gliomas are the most common primary malignant brain tumors, for which maximal safe surgical resection i...
Overall survival after intravenous iron use in patients with cancer and iron deficiency: A propensity-matched real-world study.
11128 Background: Iron deficiency affects up to two-thirds of patients with cancer and frequently coexists with anemia, wi...
Determinants of trial completion, termination, and efficacy in solid tumor immunotherapy: Mapping IO clinical trial evolution from 2015-2022.
e23326 Background: Clinical trial success depends not only on scientific rationale but also on trial design and strategic...
A pilot study of a personalized cancer vaccine in combination with immune checkpoint inhibitor in advanced pancreatic cancer.
e16434 Background: Neoantigens, derived from somatic mutations, have emerged as a compelling therapeutic target. Vaccines...
Prevalence of cardiovascular, kidney, and metabolic disease in breast and lung cancer patients in the United States.
e23081 Background: Cardiovascular, kidney, and metabolic (CKM) diseases impact cancer treatment tolerance and outcomes. We...
Long-term outcomes with sustained minimal residual disease (MRD) negativity in belantamab mafodotin–treated patients (pts) with relapsed/refractory multiple myeloma (RRMM): An update from DREAMM-8.
7515 Background: B-cell maturation antigen (BCMA)–directed therapies have changed the RRMM treatment landscape. In the pha...
Adjuvant nivolumab in addition to postoperative radiation therapy in locally advanced head and neck cancer: Results of the phase II NadiHN trial.
6092 Background: The benefit of adding immune checkpoint inhibition to standard postoperative adjuvant radiotherapy in pat...
Beyond rule-based matching: A locally deployable retrieval-augmented framework for clinical trial prescreening.
e13678 Background: Enrollment in clinical trials is critically hindered by the administrative burden of manually matching...
Neoadjuvant systemic therapy for triple-negative breast cancer: A safety-net health system’s experience.
e13127 Background: Pembrolizumab-based neoadjuvant chemoimmunotherapy has become a standard of care for stage II–III tripl...
Beta-blocker use at immune checkpoint inhibitor initiation and survival in advanced solid tumors: A multi-institutional real-world cohort study.
e14544 Background: Preclinical data suggest that β-adrenergic signaling may impair antitumor immunity and modulate respons...
A phase 3 randomized trial comparing temozolomide with PCV as adjuvant chemotherapy in grade 2 and 3 diffuse gliomas in adults.
TPS2104 Background: Both Temozolomide (TMZ) and PCV are standard adjuvant chemotherapy regimens used in treatment of grade...
Prognostic significance of CD8+T lymphocytes and CD68+ macrophages in assessing pathologic response in pediatric soft tissue sarcomas.
10042 Background: The tumor immune microenvironment (TIME) plays a critical role in treatment response in pediatric oncolo...